Most Recent Flipbooks
How Roche Optimized its Global Safety Reporting Process for Clinical Trials
Roche recognized several major challenges that its CTSP 2.0 system needed to address.
Recruitment Success - 70% of Total Randomization
Bringing the Power of Genetics to a Rare Disease Gene Therapy Program
On-Site Recruitment Success - 6x Increase in Enrollment Rate
Case Study: Initiating Sites Faster Through Efficient Contracts and Payments
Clinical Trial Recruitment for Osteoartritis Study
Rare Disease Case Study: Pediatric Sickle Cell Anemia
Our client, a Top 10 pharmaceutical company, needed to boost enrollment for their phase ll pediatric sickle cell anemia study.
Rare Disease Case Study: Familial Amyloidosis
Our client, a top-tier CRO, was faced with the challenge of enrolling for a non-interventional screening study in the familial amyloidotic cardiomyopathy (FAC) patient population.
Patient Recruitment for Ophthalmology Study (Glaucoma and Retinal Disease)
A leading pharma company needed assistance to rescue their enrolling ophthalmology study. The sponsor was attempting to complete enrollment for a normative, glaucoma and retinal disease study.
Patient Recruitment for Multi-Protocol Global Program (Phase III Cardiovascular Disease)
Our customer needed support for a global, multi-protocol program which was behind with enrollment.
Patient Recruitment for Phase IB Tobacco Research Study
A top-tier CRO had been running their study for six months when enrollment, as well as new screenings, had plateaued.
Patient Recruitment for Phase II Dermatology Study in US & Europe
Enrollment for this 100-patient study had been underway for 11 months across 32 sites globally, yet only 20 patients had been enrolled. We utilized strategic media buys to jump start enrollment.
Patient Recruitment for Obesity Implant Device Study
The sponsor needed to complete enrollment in less than six months to meet the enrollment goal of randomized 230 patientsacross only 10 sites, with a protocol containing very restrictive I/E criteria.
Patient Identification for Phase II Arthritis Drug Study in US & Europe
The challenge: complete as many randomizations as possible with extremely narrow inclusion criteria, using only “in-practice” patients within the sites' or referring physicians' databases.
Patient Enrollment for Neurostimulation Device Study
Challenge: meet time-sensitive enrollment goal of 496 patients in order to extend labeling for FDA-approved neurostimulation device for the treatment of peripheral neuropathy in post-stroke patients.
Clinical Trial Enrollment for Phase II Heart Failure Study
Challenge: jump-start enrollment in the US for this large international study so that early enrollment rates did not fall behind projections.
Patient Enrollment for Phase II Arthritis Drug Trial in US & Europe
Challenge: Meet the one year enrollment timeline for this 216 patient study. When WCG ThreeWire was engaged, total enrollment stood at only 70 patients after six months.
Patient Enrollment for Phase II Heart Failure Study
Clinical Trial Advertising for Phase II Parkinson's Disease Study
Enrollment for this 60-patient study had been underway for one year with 35 subjects enrolled. The sponsor had a 90-day deadline for randomizing the remaining 25 subjects
Trial Enrollment Advertising for Phase II Constipation Drug